论文部分内容阅读
目的:评价伏立康唑对患儿白血病伴侵袭性肺部真菌感染的临床疗效。方法:选取2014年1月—2016年1月期间收治的白血病伴有侵袭性肺部真菌感染患儿30例,患儿经诊断为白血病伴有侵袭性肺部真菌感染后给予伏立康唑治疗,临床症状较轻的患儿给予口服伏立康唑治疗,临床症状较重的患儿给予伏立康唑注射液静脉滴注治疗,治疗时间为2周~3月不等;评价患儿治疗后的总有效率以及不良反应的发生率。结果:30例患儿给予伏立康唑治疗后的总有效率为85.33%,用药期间不良反应症状较轻,具有良好的难受性。结论:采用伏立康唑治疗儿童白血病侵袭性肺部真菌感染的疗效较显著,具有较高的安全性。
Objective: To evaluate the clinical efficacy of voriconazole in children with leukemia and invasive pulmonary fungal infection. Methods: Thirty children with leukemia and invasive pulmonary fungal infection were enrolled in this study. The children were diagnosed as leukemia with invasive pulmonary fungal infection and then treated with voriconazole. The clinical symptoms Children with mild voriconazole oral treatment, clinical symptoms were given to children with voriconazole injection intravenously, treatment time ranging from 2 weeks to March; evaluation of children with total effective rate of treatment and adverse reactions Occurrence rate. Results: The total effective rate of voriconazole after treatment in 30 children was 85.33%. The symptoms of adverse reactions during treatment were mild and had good discomfort. Conclusion: Voriconazole treatment of childhood leukemia invasive pulmonary fungal infection more significant effect, with high safety.